Medpace (MEDP)
(Delayed Data from NSDQ)
$337.28 USD
+2.13 (0.64%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $346.79 +9.51 (2.82%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MEDP 337.28 +2.13(0.64%)
Will MEDP be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for MEDP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEDP
Medpace (MEDP) Stock Moves -0.36%: What You Should Know
PACS vs. MEDP: Which Stock Is the Better Value Option?
MEDP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medpace (MEDP) Tops Q3 Earnings Estimates
Medpace (MEDP) Rises Higher Than Market: Key Facts
Medpace (MEDP) Laps the Stock Market: Here's Why
Other News for MEDP
Miller-Howard Small Cap Dividend Q3 2024 Commentary
Truist Financial Issues a Hold Rating on Medpace Holdings (MEDP)
10 Health Care Stocks Whale Activity In Today's Session
Invesco Discovery Fund Q3 2024 Commentary
Invesco Health Care Fund Q3 2024 Commentary